Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Fall Home Improvement
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Services
2023 Readersâ Choice Winners
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Coherus Bio
(NQ:
CHRS
)
2.420
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
-
Bid (Size)
2.330 (1)
Ask (Size)
2.410 (4)
Prev. Close
2.420
Today's Range
2.420 - 2.420
52wk Range
1.430 - 8.650
Shares Outstanding
112,714,488
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Why Coherus Biosciences Stock Tumbled on Thursday
March 14, 2024
The company fell well short of expectations for its fourth quarter.
Via
The Motley Fool
Recap: Coherus BioSciences Q4 Earnings
March 13, 2024
Via
Benzinga
Performance
YTD
-22.93%
-22.93%
1 Month
-3.20%
-3.20%
3 Month
-10.04%
-10.04%
6 Month
-39.04%
-39.04%
1 Year
-62.31%
-62.31%
More News
Read More
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
March 13, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Earnings Preview For Coherus BioSciences
March 12, 2024
Via
Benzinga
Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
March 05, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Earnings Scheduled For March 13, 2024
March 13, 2024
Via
Benzinga
Coherus Completes Divestiture of Ophthalmology Franchise
March 04, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus BioSciences Announces New Employment Inducement Grants
February 23, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
February 21, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Why Coherus BioSciences Stock Jumped Today
February 06, 2024
Via
The Motley Fool
Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP
February 05, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Why Coherus BioSciences Stock Is Sinking Today
January 23, 2024
Via
The Motley Fool
Why Coherus Biosciences Popped Today
January 22, 2024
Via
The Motley Fool
Why CommScope Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session
January 22, 2024
Via
Benzinga
Why Is Cancer Immunotherapy Focused-Coherus BioSciences Stock Trading Higher Today?
January 22, 2024
Via
Benzinga
Why Is Cartesian Therapeutics (RNAC) Stock Down 5% Today?
January 22, 2024
Via
InvestorPlace
Why Is B. Riley Financial (RILY) Stock Down 11% Today?
January 22, 2024
Via
InvestorPlace
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
Why Is Coherus BioSciences (CHRS) Stock Up 17% Today?
January 22, 2024
Via
InvestorPlace
Why Coherus BioSciences Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket
January 22, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
January 22, 2024
Via
InvestorPlace
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal
January 22, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
January 19, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
January 18, 2024
Via
Benzinga
Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium
January 18, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Veradigm, Aehr Test Systems, Saratoga Investment And Other Big Stocks Moving Lower On Wednesday
January 10, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.